Innovation Hub
/
Blog
/
New Drugs Using Only a Computer, the Internet and Free Online Data

New Drugs Using Only a Computer, the Internet and Free Online Data

Sean Preci

Published on

May 6, 2016

Pharmaceutical companies typically develop new drugs with thousands of staff and budgets that run into the billions of dollars. One estimate puts the cost of bringing a new drug to market at $2.6 billion with others suggesting that it could be double that cost at $5 billion.

Take the Next Step

Explore Suppliers

Browse trusted partners with relevant expertise

Review Capabilities

Compare services, experience, and past work

Start Your Project

Connect and begin collaborating

Browse Suppliers

Post a Project

How It Works

Written by

Sean Preci

Share this post

TOPICS

Pharmacology

Subscribe to our newsletter

Subscribe to receive the latest news and innovations straight to your inbox.

Your subscription could not be saved. Please try again.

Your subscription has been successful.

Topics of Interest

Biology
Biometrics
Chemical & Compound Analysis
Chemistry, Manufacturing & Controls
Clinical Trials
Discovery Chemistry
DMPK
Health Economics & Outcomes Research (HEOR)
Human Biological Samples (HBS)
Market Access
Non-Human Biological Samples (NHBS)
Pharmacology
Raw Materials
Real-World Data (RWD)
Real-World Evidence (RWE)
Safety & Pharmacovigilance
Toxicology
Medical Communications

Email address

I would like to receive the monthly Scientist.com newsletter.

I agree to receive email communication from Scientist.com and accept the data privacy statement.

By submitting your information, you agree to our Terms of Service and Privacy Policy. You can opt out anytime.

New Drugs Using Only a Computer, the Internet and Free Online Data

Take the Next Step

Explore Suppliers

Review Capabilities

Start Your Project

Subscribe to our newsletter

Read Futher

Speed Matters: Why RWE Acceleration Starts Upstream with Reusable Data

Industry Insights: Behind the Scenes of BPS Bioscience Custom R&D

Making Sustainability More "Sustainable": Driving Transformation at Scale within Biopharma

Comprehensive Plasma cell-free RNA Profiling for Superior Cancer Detection

Advanced Screening Strategies for Molecular Glue Discovery

Why Large CROs and CDMOs Should Embrace Research Orchestration Platforms - Even with Existing Pharma Clients

AI in HEOR: Three Ways Artificial Intelligence Is Accelerating Evidence Generation

Supplier Spotlight: RadMD Imaging

INsights & OUTcomes with Mark Larkin

AI Is Expanding What's Possible in Drug Discovery. Operational Friction Still Determines How Fast It Happens.

The Science of the "Gut Feeling": Why Techs are a Lab's Best Diagnostic Tool

Supplier Spotlight: MedChemExpress

Cell Line-Derived Xenografts: A Reliable Platform for Preclinical Cancer Drug Testing

2026 PharmDev Roadmap: The Regulatory Shift

INsights & OUTcomes with Radek Wasiak

Five Reasons Leading CNS Programs Rely on BrainXell for Custom iPSC Models

From the Colony to the Roadmap: The FDA's New Stance on NAMs and Why it Matters

2026 PharmDev Roadmap: The Strategic Partner

2026 PharmDev Roadmap: The Predictive Model

INsights & OUTcomes with Taylor Hirschberg

2026 PharmDev Roadmap: The Complexity Spike

Explore FUJIFILM's Cyclic Peptide Discovery Service

2026 PharmDev Roadmap: The Resilience Pivot

The Biosecure Act: Navigating Changes in the Biopharma Supply Chain

Evolving Frontiers in Immunohistochemistry: Applications and Transformations in Modern Biotechnology

Supplier Spotlight: Shuimu Biosciences

2025 Year in Review

Beyond the Bead: 10 Questions on How to Improve the Reliability of Flow Cytometry Controls with Precision-Engineered Cell Mimics

Your Guide to Chemistry, Manufacturing, and Controls (CMC) Events in 2026

Must-Attend Biotech and Pharma Conferences of 2026

Read Further

INsights & OUTcomes with Mark Larkin

AI in HEOR: Three Ways Artificial Intelligence Is Accelerating Evidence Generation

Speed Matters: Why RWE Acceleration Starts Upstream with Reusable Data

Streamlining Supplier Onsite Pre-Assessments: Insights From an Independent Auditor

The Digital Backbone for Modern Life Sciences